Search results for "Cooking"

showing 10 items of 635 documents

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study

2012

Abstract AIM: To investigate the clinical course of untreatable hepatocellular carcinoma (HCC) identified at any stage and to identify factors associated with mortality. METHODS: From January 1999 to December 2010, 320 out of 825 consecutive patients with a diagnosis of HCC and not appropriate for curative or palliative treatments were followed and managed with supportive therapy. Cirrhosis was diagnosed by histological or clinical features and liver function was evaluated according to Child-Pugh score. The diagnosis of HCC was performed by Ultra-Sound guided biopsy or by multiphasic contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging. Data were collected…

Oncologymedicine.medical_specialtyBrief ArticleHepatologybusiness.industryClinical courseCancerRetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryNatural historyInternal medicineHepatocellular carcinomamedicinehepatocellular carcinoma survival natural historyStage (cooking)businessWorld Journal of Hepatology
researchProduct

Ovarian Cancer: Primary Advanced and Recurrent Disease

2021

Approximately 70% of patients affected by epithelial ovarian cancer (EOC) are diagnosed with FIGO stage III–IV disease and 50–70% of them will develop a recurrence, after a median progression-free survival (PFS) of approximately 18 months. The 5-year survival for stage III and IV ranges from 39% to 17%, respectively. Treatment options for primary advanced and recurrent disease comprehend surgery (primary cytoreductive surgery or interval cytoreductive surgery after neoadjuvant chemotherapy for primary advanced disease and secondary cytoreductive surgery for recurrent disease) and systemic therapy (standard and novel chemotherapeutic agents and biological agents).

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentTreatment optionsDiseasemedicine.diseaseSystemic therapyInternal medicinemedicineRecurrent diseaseEpithelial ovarian cancerStage (cooking)businessOvarian cancer
researchProduct

Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia

2008

Chronic lymphocytic leukemia is an adult-onset leukemia with a heterogeneous clinical behavior. When chronic lymphocytic leukemia cases were divided on the basis of IgVH mutational status, widely differing clinical courses were revealed. Since IgVH sequencing is difficult to perform in a routine diagnostic laboratory, finding a surrogate for IgVH mutational status seems an important priority. In the present study, we proposed the use of Cryptochrome- 1 as a new prognostic marker in early-stage chronic lymphocytic leukemia. Seventy patients (Binet stage A, without treatment) were included in the study. We correlated Cryptochrome-1 mRNA with well established prognostic markers such as IgVH mu…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaIgV(H)ZAP70 LPL IgVHImmunoglobulin E:CIENCIAS MÉDICAS ::Patología::Hematología [UNESCO]Prognostic markerPredictive Value of TestsInternal medicinemedicineHumansUNESCO::CIENCIAS MÉDICAS ::Patología::HematologíaRNA MessengerStage (cooking)HematologybiologyFlavoproteinsZAP70CancerHematologyCryptochrome-1medicine.diseasePrognosis:CIENCIAS MÉDICAS [UNESCO]Leukemia Lymphocytic Chronic B-CellCryptochromesLeukemiaUNESCO::CIENCIAS MÉDICAS ::Patología::OncologíaImmunologyUNESCO::CIENCIAS MÉDICASbiology.proteinZAP70Brief ReportsChronic lymphocytic leukemiaAntibodyLPL:CIENCIAS MÉDICAS ::Patología::Oncología [UNESCO]BiomarkersCryptochrome-1 ; Prognostic marker ; Chronic lymphocytic leukemia ; ZAP70 LPL IgVH
researchProduct

CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2…

2021

Adjuvant colon cancer (CC) therapy and survival have greatly evolved over the last decades. Research shifted towards a more biological tumour understanding and unlocked new therapies and disease mo...

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industrymedicine.medical_treatmentMEDLINEHematologyGeneral MedicineDiseasemedicine.diseaseCXCR4OncologyInternal medicinePost-hoc analysismedicineRadiology Nuclear Medicine and imagingStage (cooking)businessAdjuvantActa Oncologica
researchProduct

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

2005

In the last two decades the results of medical treatment of advanced non-small cell lung cancer (NSCLC) have constantly improved even if they are still far from being considered satisfactory. Today systemic cisplatin-based chemotherapy (CT) is able to increase survival and improve cancer-related symptoms in patients with advanced ‘wet’ stage III and metastatic stage IV NSCLC, but it not clear if the benefits of CT also apply to patients with poor performance status (PS) [1, 2]. PS is the most powerful independent prognostic factor in advanced NSCLC since it is a reliable measure of functional independence, ability to perform daily activities and work, and a strong predictor of survival and …

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryDrugs Investigationallung cancer performance status 2 chemotherapy best supportive careHematologymedicine.diseaseClinical trialRegimenOncologyQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansControlled Clinical Trials as TopicStage (cooking)Lung cancerbusinessAdverse effectSurvival rateSurvival analysisNeoplasm StagingAnnals of Oncology
researchProduct

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (…

2010

Abstract Abstract 1360 The arbitrary cut-off of 5000/μL chronic lymphocytic leukemia (CLL)-phenotype cells in peripheral blood is generally used to separate monoclonal B-cell lymphocytosis (MBL) from CLL. However, a major concern is the biological differentiation, if any, between MBL and CLL. We tried to address the issue therefore analyzing 261 Rai stage 0 patients enrolled in a Gruppo Italiano Studio Linfomi (GISL) prospective multicentre trial designed to validate biological parameters in early CLL as well as to assess the impact on clinical outcome of an early versus delayed policy of treatment with subcutaneous alemtuzumab in the high biological risk. In this cohort, biological charact…

Oncologymedicine.medical_specialtyLymphocytosisbusiness.industryChronic lymphocytic leukemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryPeripheral bloodhemic and lymphatic diseasesInternal medicineMonoclonalCohortmedicineAlemtuzumabMonoclonal B-cell lymphocytosisStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

2017

Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984-2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984-2011). Median follow-up was 64.6 months. Differences betwe…

Oncologymedicine.medical_specialtyMultidisciplinarybusiness.industryProportional hazards model030232 urology & nephrologyRetrospective cohort studymedicine.diseaseMetastasis03 medical and health sciencesClear cell renal cell carcinoma0302 clinical medicineRenal cell carcinoma030220 oncology & carcinogenesisInternal medicineCarcinomaMedicineCumulative incidenceStage (cooking)businessPLOS ONE
researchProduct

What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?

2021

Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods: We enrolled patients who underwent surgery for endometrial cancer between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-quantitative way, according to a 3-tiered scoring system in absent, focal and substantial. Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal LVSI (n=35, 6.7%) and substantial LVSI (n=2…

Oncologymedicine.medical_specialtyMultivariate analysisLymph node metastasisEndometrial Cancer03 medical and health sciences0302 clinical medicineText miningInternal medicineMedicineHumansRisk factorStage (cooking)Neoplasm MetastasisLetter to the EditorUnivariate analysis030219 obstetrics & reproductive medicineEndometrial Cancer; Neoplasm Metastasis; Prognostic FactorsEndometrial Cancer Neoplasm Metastasis Prognostic Factorsbusiness.industryPrognostic FactorsEndometrial cancerHazard ratioCancerObstetrics and GynecologyGeneral Medicinemedicine.diseasePrognosisLymphovascularEndometrial NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionFemaleLymphNeoplasm Recurrence LocalbusinessCarcinoma EndometrioidJournal of gynecologic oncology
researchProduct

From palliation to cure: PIPAC for peritoneal malignancies

2019

Introduction Systemic chemotherapy offers poor control over peritoneal disease, maybe as a consequence of restricted drug availability within the abdominal cavity. Locoregional chemotherapy may overcome these shortcomings but its administration is limited to a few patients with confined peritoneal spread. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) emerged in the last years as a novel method of intraperitoneal drug administration. Evidence acquisition We report a meta-analysis of published studies on PIPAC safety and pathological anti-tumoral efficacy on PC from various tumor entities, with the aim of providing more evidence to support further research. This systematic review a…

Oncologymedicine.medical_specialtyPalliative caremedicine.medical_treatmentSettore MED/25 - PSCHIATRIAAntineoplastic AgentsAbdominal cavityDisease03 medical and health sciences0302 clinical medicineInternal medicinemedicinePressureHumansStage (cooking)Adverse effectAerosolsChemotherapybusiness.industryRemission InductionGeneral MedicinePeritoneal carcinomatosisPeritoneal neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisMeta-analysisPalliative care030211 gastroenterology & hepatologyDrug therapyPeritoneumbusiness
researchProduct

Histopathologic risk factors in oral and oropharyngeal squamous cell carcinoma variants: An update with special reference to HPV-related carcinomas

2014

Accurate identification of the microscopic risk factors of oral and oropharyngeal (OP) squamous cell carcinomas (SCC) and their morphologic variants is of at most importance, as these generally determine treatment modalities, prognosis and overall patient outcome. The great majority of oral and oropharyngeal squamous cell carcinomas are microscopically described as kerartinizing squamous cell carcinoma (KSCC). They bear certain resemblance to keratinizing stratified squamous epithelium. Tobacco habits and excessive consumption of alcoholic beverages have been considered to be the main etiologic agents in these carcinomas. The tumors occurred in older patients more commonly affected the oral…

Oncologymedicine.medical_specialtyPathologyOdontologíaStratified squamous epitheliumReviewSmall-cell carcinomaRisk FactorsInternal medicinemedicineCarcinomaHumansStage (cooking)Basaloid Squamous Cell CarcinomaGeneral DentistryMouth neoplasmOral Medicine and Pathologybusiness.industryPapillomavirus Infections:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludHead and neck squamous-cell carcinomastomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOropharyngeal NeoplasmOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellSurgeryMouth NeoplasmsbusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct